The Top 5 Biosimilars Articles for the Week of August 27

The Center for Biosimilars® recaps the top news for the week of August 27, 2018.

Transcript:

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of August 27.

Number 5: The Canadian province of British Columbia will begin reimbursing for a second biosimilar infliximab.

Number 4: Carlos Sattler, head of clinical development and medical affairs at Sandoz, spoke with The Center for Biosimilars® about the biosimilar development process and the regulatory landscape that lies ahead.

Number 3: The World Health Organization says that promoting the uptake of lower-priced medicines such as generics and biosimilars will “facilitate efficiency gains without disadvantaging patients.”

Number 2: Gillian Woollett of Avalere Health says many phase 3 trials of biosimilars lack scientific and ethical validity.

Number 1: Pfizer has submitted a citizen petition to the FDA that asks for guidance that clarifies how drug sponsors may communicate about biosimilars.

Finally, last week, our e-newsletter asked whether you think that a new CVS Caremark policy that will allow health plans to exclude high-cost drugs will result in better negotiation on drug prices.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.